|
| | Tenofovir alafenamide hemifumarate Basic information |
| Product Name: | Tenofovir alafenamide hemifumarate | | Synonyms: | L-Alanine,N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester, (2E)-2-butenedioate (2:1);N-[(S)-[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-L-alanine 1-methylethyl ester (2E)-2-butenedioate (2:1);GS-7340 (hemifumarate);TENOFOVIR ALAFENAMIDE HEMIFUMARATE (GS-7340 HEMIFUMARATE);Tenofovir levamide amine fumarate;GS7340(Tenofovir Alafenamide Fumarate);(Tenofovir alafenamide : fumarate = 2:1);Anti-HIV | | CAS: | 1392275-56-7 | | MF: | C25H33N6O9P | | MW: | 592.55 | | EINECS: | 805-448-8 | | Product Categories: | API;1392275-56-7 | | Mol File: | 1392275-56-7.mol |  |
| | Tenofovir alafenamide hemifumarate Chemical Properties |
| storage temp. | Keep in dark place,Sealed in dry,Room Temperature | | solubility | DMSO:75.0(Max Conc. mg/mL);70.16(Max Conc. mM) | | CAS DataBase Reference | 1392275-56-7 |
| | Tenofovir alafenamide hemifumarate Usage And Synthesis |
| Description | Tenofovir alafenamide hemifumarate is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. | | Chemical Properties | White to almost White crystal or crystalline powder. | | Originator | Gilead Sciences | | Uses | Tenofovir alafenamide hemifumarate is a newer, more effective prodrug used in combination with FTC that has recently been approved for the prevention of HIV transmission through the rectum. It is used to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. | | Definition | ChEBI: A fumarate salt prepared from tenofovir alafenamide by reaction of one molecule of fumaric acid for every two molecules of tenofovir alafenamide. A prodrug for tenofovir, it is used in combination therapy for the treatment of HIV-1 infection. | | Side effects | Check with your doctor immediately if any of the following side effects occur:
Abdominal or stomach discomfort,bloody urine,dark urine,decreased appetite,decreased frequency or amount of urine,troubled breathing,cough,headache,back pain. | | Synthesis | Under a nitrogen atmosphere, 200 g of isopropanol, 9 g of fumaric acid, and 50 g of TAF-3 were sequentially added to a 2 L reaction flask. Turn on the stirring, control the temperature at 40 ~ 50 °C, stir and dissolve, filter while hot, collect the mother liquor. Transfer the mother liquor to a 2L reaction bottle, start stirring, control the temperature at 40 ~ 50 °C, stir and dissolve, slowly reduce the temperature to 0 ~ 5 ° C, cooling time 2 ~ 3 hours, heat stirring for 10 hours. Filtration, drying at 60-65 ° C for 12 to 16 hours, to obtain 37.5 g of Tenofovir Alafenamide Fumarate finished product, white powder, yield 75.0%.
|
| | Tenofovir alafenamide hemifumarate Preparation Products And Raw materials |
|
